Perfil
Marlies Sproll served as the Chief Scientific Officer at MorphoSys AG from 2000 to 2017.
Prior to that, she worked at Lanthio Pharma BV as a Member-Supervisory Board.
Dr. Sproll earned a doctorate degree from Max Planck Institute for Metals Research.
Antiguos cargos conocidos de Marlies Sproll.
| Empresas | Cargo | Fin |
|---|---|---|
| MORPHOSYS AG | Chief Tech/Sci/R&D Officer | 15/04/2017 |
Lanthio Pharma BV
 Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Director/Board Member | - |
Formación de Marlies Sproll.
| Max Planck Institute for Metals Research | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| MORPHOSYS AG | Health Technology |
| Empresas privadas | 1 |
|---|---|
Lanthio Pharma BV
Lanthio Pharma BV Medical SpecialtiesHealth Technology Lanthio Pharma BV focuses on discovering and developing lantipeptides for the generation of novel peptide therapeutics. Its product is a lanthionine-stabilized specific agonist of the AT2 receptor, which has great potential in diseases where tissue protection is important, like fibrosis. The company was founded in 2010 and is headquartered in Groningen, the Netherlands. | Health Technology |
- Bolsa de valores
- Insiders
- Marlies Sproll
